GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
PHILADELPHIA, PA – The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate ...
The 25-year follow-up of the GÖTEBORG-1 trial 5 assessing active surveillance for screen-detected low and intermediate risk ...
Findings are among nine Decipher-focused abstracts being presented at annual conference “We look forward to the presentation of important new data examining the role of adverse molecular features in ...
The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results